Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.

Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations. Heart Rhythm (2011) 1.44

Dynamics of heat shock protein 90 C-terminal dimerization is an important part of its conformational cycle. Proc Natl Acad Sci U S A (2010) 1.17

Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opin Emerg Drugs (2009) 1.12

New pharmacological strategies for the treatment of atrial fibrillation. Ann Noninvasive Electrocardiol (2009) 1.02

Mechanisms of termination and prevention of atrial fibrillation by drug therapy. Pharmacol Ther (2011) 0.94

Dronedarone. Nat Rev Drug Discov (2009) 0.93

How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation? J Atr Fibrillation (2008) 0.90

Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol. Circ Arrhythm Electrophysiol (2012) 0.88

Vanoxerine: cellular mechanism of a new antiarrhythmic. J Cardiovasc Electrophysiol (2009) 0.86

Novel anti-arrhythmic medications in the treatment of atrial fibrillation. Curr Cardiol Rev (2012) 0.82

Can we improve outcomes in AF patients by early therapy? BMC Med (2009) 0.81

Pharmacological management of atrial fibrillation: one, none, one hundred thousand. Cardiol Res Pract (2011) 0.80

A novel treatment strategy of new onset atrial fibrillation after cardiac surgery: an observational prospective study. J Cardiothorac Surg (2014) 0.80

Beta1-adrenoceptor polymorphism predicts flecainide action in patients with atrial fibrillation. PLoS One (2010) 0.80

Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study. Clin Res Cardiol (2010) 0.79

Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation--a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study). Trials (2012) 0.79

Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update. Vasc Health Risk Manag (2013) 0.78

Early management of atrial fibrillation: from imaging to drugs to ablation. Nat Rev Cardiol (2010) 0.78

Vernakalant. Nat Rev Drug Discov (2010) 0.77

The vernakalant story: how did it come to approval in Europe and what is the delay in the U.S.A? Curr Cardiol Rev (2014) 0.77

New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant. J Interv Card Electrophysiol (2008) 0.76

Medication management of atrial fibrillation: emerging therapies for rhythm control and stroke prevention. P T (2011) 0.75

Drug therapy in atrial fibrillation management: where do we stand in 2010? J Tehran Heart Cent (2010) 0.75

How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation? J Atr Fibrillation (2008) 0.75

Suitability, efficacy, and safety of vernakalant for new onset atrial fibrillation in critically ill patients. Crit Care Res Pract (2014) 0.75

Advances in the Pharmacological Treatment of Atrial Fibrillation. Curr Med Lit Cardiol (2010) 0.75

Meta-analysis of effect of vernakalant on conversion of atrial fibrillation. BMC Res Notes (2013) 0.75

Rhythm control strategies and the role of antiarrhythmic drugs in the management of atrial fibrillation: focus on clinical outcomes. J Gen Intern Med (2010) 0.75

Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial. BMC Cardiovasc Disord (2016) 0.75

Current issues in atrial fibrillation. ISRN Cardiol (2012) 0.75

The burden of proof: The current state of atrial fibrillation prevention and treatment trials. Heart Rhythm (2017) 0.75

Rate-Dependent Role of IKur in Human Atrial Repolarization and Atrial Fibrillation Maintenance. Biophys J (2017) 0.75

Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department. Europace (2017) 0.75

Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation in the Asia-Pacific region: a phase 3 randomized controlled trial. J Cardiovasc Pharmacol (2016) 0.75

[New developments in the antiarrhythmic therapy of atrial fibrillation]. Herzschrittmacherther Elektrophysiol (2010) 0.75

Emerging therapies for atrial fibrillation: is the paradigm shifting? J Interv Card Electrophysiol (2010) 0.75

[Medicinal rhythm control in atrial fibrillation]. Herzschrittmacherther Elektrophysiol (2014) 0.75

Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med (2005) 27.36

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39

Universal definition of myocardial infarction. Circulation (2007) 11.69

ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 11.49

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (2003) 9.80

Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93

Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51

2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm (2012) 8.03

Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation (2006) 7.01

Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med (2013) 6.40

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31

Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol (2006) 6.11

ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 5.95

Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ (2011) 5.84

2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace (2012) 5.84

ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol (2006) 5.81

Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet (2007) 5.21

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16

Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med (2003) 5.12

Prophylactic Oral Amiodarone for the Prevention of Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: a randomized controlled trial. JAMA (2005) 5.11

Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation (2011) 4.90

Single-chamber versus dual-chamber pacing for high-grade atrioventricular block. N Engl J Med (2005) 4.80

Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med (2012) 4.69

High risk clinical characteristics for subarachnoid haemorrhage in patients with acute headache: prospective cohort study. BMJ (2010) 4.65

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med (2010) 4.52

Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46

Clinical decision rules to rule out subarachnoid hemorrhage for acute headache. JAMA (2013) 4.34

HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm (2011) 4.31

Resting heart rate in cardiovascular disease. J Am Coll Cardiol (2007) 4.14

Derivation of the San Francisco Syncope Rule to predict patients with short-term serious outcomes. Ann Emerg Med (2004) 4.12

Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation (2004) 4.04

CATCH: a clinical decision rule for the use of computed tomography in children with minor head injury. CMAJ (2010) 4.03

Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med (2010) 4.01

Drug induced QT prolongation and torsades de pointes. Heart (2003) 3.97

Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA (2006) 3.84

Out-of-hospital pediatric cardiac arrest: an epidemiologic review and assessment of current knowledge. Ann Emerg Med (2005) 3.79

A trial of an impedance threshold device in out-of-hospital cardiac arrest. N Engl J Med (2011) 3.76

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J (2011) 3.72

Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet (2008) 3.71

Comparison of the 20-hour intravenous and 72-hour oral acetylcysteine protocols for the treatment of acute acetaminophen poisoning. Ann Emerg Med (2009) 3.67

Derivation and validation of an index to predict early death or unplanned readmission after discharge from hospital to the community. CMAJ (2010) 3.60

ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol (2003) 3.55

Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. Circulation (2008) 3.54

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace (2006) 3.52

Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation (2009) 3.50

Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med (2008) 3.49

Prognosis among healthy individuals discharged with a primary diagnosis of syncope. J Am Coll Cardiol (2012) 3.33

Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation (2012) 3.30

Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation (2008) 3.23

Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J (2004) 3.14

Chelation therapy for ischemic heart disease: a randomized controlled trial. JAMA (2002) 3.13

The Canadian C-spine rule performs better than unstructured physician judgment. Ann Emerg Med (2003) 3.12

ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace (2006) 3.11

Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol (2013) 3.06

The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis (2011) 2.95

Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med (2014) 2.91

Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med (2010) 2.90

Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension (2013) 2.89

Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA (2012) 2.85

Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock: a randomized, placebo controlled trial. Ann Surg (2011) 2.85

Sensitivity of computed tomography performed within six hours of onset of headache for diagnosis of subarachnoid haemorrhage: prospective cohort study. BMJ (2011) 2.82

Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation (2004) 2.81

Prevalence of information gaps in the emergency department and the effect on patient outcomes. CMAJ (2003) 2.76

Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension (2012) 2.75

Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. J Hypertens (2009) 2.71

Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes. JAMA (2012) 2.69

ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation (2003) 2.68

Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA (2010) 2.68

The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ (2012) 2.65

Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension (2010) 2.64

Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of "normal weight central obesity". J Am Coll Cardiol (2013) 2.61

The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol (2009) 2.59

Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation (2007) 2.59

Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation (2006) 2.58

HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace (2011) 2.54

ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J (2006) 2.54

EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J (2013) 2.52

Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet (2009) 2.51

Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data. J Am Coll Cardiol (2011) 2.50

Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation (2010) 2.46

Prospective validation of the ABCD2 score for patients in the emergency department with transient ischemic attack. CMAJ (2011) 2.45

Optimal defibrillation response intervals for maximum out-of-hospital cardiac arrest survival rates. Ann Emerg Med (2003) 2.42

Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. J Am Coll Cardiol (2011) 2.42

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace (2015) 2.35

Ambulatory blood pressure and mortality: a population-based study. Hypertension (2005) 2.34

Ambulatory blood pressure monitoring in 9357 subjects from 11 populations highlights missed opportunities for cardiovascular prevention in women. Hypertension (2011) 2.33

Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J (2011) 2.30

Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J (2005) 2.28

Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens (2010) 2.28

Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individuals. J Hypertens (2007) 2.26

Effect of real-time feedback during cardiopulmonary resuscitation outside hospital: prospective, cluster-randomised trial. BMJ (2011) 2.22

Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost (2011) 2.22

The out-of-hospital validation of the Canadian C-Spine Rule by paramedics. Ann Emerg Med (2009) 2.17

An initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction. J Am Coll Cardiol (2006) 2.16

Retrospective application of the NEXUS low-risk criteria for cervical spine radiography in Canadian emergency departments. Ann Emerg Med (2004) 2.15